Fate Therapeutics director granted 87,900 options

Fate Therapeutics director Shefali Agarwal received a new stock option grant covering 87,900 shares of common stock.

Rhea-AI Filing Summary

Fate Therapeutics director Shefali Agarwal received a new stock option grant covering 87,900 shares of common stock. The option has an exercise price of $2.06 per share and expires on June 12, 2036. It will vest and become exercisable on the earlier of June 12, 2027 or the company’s 2027 Annual Meeting of Stockholders, contingent on her continued board service. Following this grant, she holds options on 87,900 shares directly.

Insider Trade Summary

Grant/Award: 87,900 shares

Grant/Award 1 txn

Insider Agarwal Shefali

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 contracts (Direct)

Footnotes (2)

1. F1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
2. F2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Key Figures

Option grant size: 87,900 shares Exercise price: $2.06 per share Expiration date: June 12, 2036 +2 more

5 metrics

Option grant size 87,900 shares Stock Option (Right to Buy) awarded to director

Exercise price $2.06 per share Stock option strike price for common stock

Expiration date June 12, 2036 Option term end date

Post-grant option holdings 87,900 shares Total derivative securities following transaction

Vesting trigger date June 12, 2027 Latest vesting date or 2027 Annual Meeting, whichever is earlier

Key Terms

Amended and Restated Non-Employee Director Compensation Policy, Annual Meeting of Stockholders, vest and become exercisable

3 terms

Amended and Restated Non-Employee Director Compensation Policy financial

"grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy"

Annual Meeting of Stockholders financial

"annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Fate Therapeutics (FATE) director Shefali Agarwal report in this Form 4?

Shefali Agarwal reported receiving a stock option grant for 87,900 shares of Fate Therapeutics common stock at a $2.06 exercise price, as part of the company’s non-employee director compensation program tied to the annual shareholder meeting.

Is the Fate Therapeutics (FATE) Form 4 transaction a market purchase or sale?

The Form 4 shows a compensation-related stock option grant, not a market purchase or sale. The options were awarded under Fate Therapeutics’ Amended and Restated Non-Employee Director Compensation Policy for service on the board of directors.

What are the vesting terms of the 87,900 Fate Therapeutics (FATE) options?

The 87,900 options vest and become exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 Annual Meeting of Stockholders, provided Shefali Agarwal continues to serve on the company’s board of directors.

What is the exercise price and expiration date of the Fate Therapeutics (FATE) options?

The options have a $2.06 per share exercise price and expire on June 12, 2036. This gives the director a long-dated right to buy Fate Therapeutics common stock if she meets the vesting and continued service conditions.

How many Fate Therapeutics (FATE) options does the director hold after this grant?

After this grant, Shefali Agarwal holds stock options covering 87,900 shares of Fate Therapeutics common stock. The Form 4 lists this as her direct derivative holdings following the reported compensation-related award transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agarwal Shefali

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		87,900		(2)	06/12/2036	Common Stock	87,900	$0	87,900	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)